HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Type II DNA Topoisomerases (Topoisomerase II)

Subscribe to New Research on Type II DNA Topoisomerases

DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex.

Also Known As:

Topoisomerase II; DNA Topoisomerase (ATP-Hydrolysing); DNA Topoisomerases, Type II; DNA Type 2 Topoisomerase; Type II DNA Topoisomerase; DNA Topoisomerase II

Networked: 1267 relevant articles (30 outcomes, 124 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 25006
  - Isomerases: 17
    - DNA Topoisomerases: 68
      - Type II DNA Topoisomerases: 1267
        DNA topoisomerase II beta: 17
        Eukaryotic Type II DNA Topoisomerases: 1
        Archaeal Type II DNA Topoisomerases
        Bacterial Type II DNA Topoisomerases
        C elegans CIN-4 protein

Experts

1.	Osheroff, Neil: 13 articles (01/2010 - 10/2002)
2.	Felix, Carolyn A: 11 articles (01/2010 - 11/2003)
3.	Nitiss, John L: 10 articles (05/2009 - 01/2002)
4.	Sehested, Maxwell: 8 articles (01/2009 - 05/2002)
5.	Jensen, Lars H: 8 articles (01/2009 - 05/2002)
6.	Cortés, Felipe: 7 articles (09/2009 - 03/2002)
7.	Jensen, Peter B: 7 articles (01/2009 - 05/2002)
8.	Ding, Jian: 7 articles (09/2008 - 08/2003)
9.	Bailly, C: 7 articles (06/2007 - 06/2000)
10.	Miao, Ze-Hong: 6 articles (02/2007 - 08/2003)

Related Diseases

1.	Neoplasms (Cancer) 09/01/1991 - "It can be interpreted from these results that topoisomerase II inhibitors could be effective in cancer patients due to the greater level of this enzyme in tumor cells than in normal tissues. " 07/01/1999 - "As a continuation of our structure-activity relationship studies, several new 4-beta-substituted 4'-O-demethyl-4-desoxypodophyllotoxins bearing mono-, di-, or trisubstituted anilines have been synthesized and evaluated as inhibitors of DNA topoisomerase II and tumor cell growth in tissue culture. " 09/01/1995 - "Studies of topoisomerase II-mediated drug-resistance in various model systems, as well as the sequencing of such mutations from drug-resistant tumors, have shed light on the functional domains of topoisomerase II, on how it interacts with inhibitors, and on the different mechanisms by which cells avoid the toxic effects of many clinically important anti-tumor drugs." 10/05/1993 - "Recent studies have demonstrated that chemotherapeutic drugs that inhibit the nuclear enzyme DNA topoisomerase II synergize with TNF in tumor cell killing in vitro and in vivo. " 01/01/1992 - "However, rTNF has synergistic anticancer effects when combined with chemotherapeutic drugs targeted at DNA topoisomerase II. This effect of rTNF has been observed in several in vitro and in vivo tumor models, both in animal and human studies. " Order ALL the reference details at left...
2.	Leukemia 04/01/1998 - "A number of recent studies have investigated the expression of topoisomerase II in clinical leukemia specimens. " 10/01/2009 - "In terms of latency, cytogenetics, and presentation, DNA topoisomerase II-targeted drug-related leukemia seemed likely for this patient. " 08/27/2009 - "In this issue of Blood, Wray and colleagues have identified a mechanism whereby acute leukemia cells use a stimulator of topoisomerase II activity to allow proliferation despite drug inhibition of this essential enzyme." 07/01/2009 - "A balanced translocation involving 11q23 (MLL gene) could be observed in therapy related leukemia (TRL) patients generally treated with topoisomerase II inhibitors. " 03/15/2008 - "A cell-based assay showed that HQ17(3) inhibited the growth of leukemia HL-60 cells with an EC50 of 0.9 microM, inhibited the topoisomerase-II-deficient cells HL-60/MX2 with an EC50 of 9.6 microM, and exerted no effect on peripheral blood mononuclear cells at concentrations up to 50 microM. " Order ALL the reference details at left...
3.	Lymphoma (Lymphomas) 07/01/2008 - "In addition, we suggest that it might be possible to use topoisomerase II inhibitor agents in high grade gastric lymphomas." 01/01/1997 - "Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells." 02/01/1993 - "Sensitivity to topoisomerase II inhibitors was tested at the cellular and enzyme level for two strains of mouse L5178Y lymphoma cells: resistant (LY-R) and sensitive (LY-S) to X-radiation. " 01/01/1989 - "The cytotoxic and mutagenic effects of topoisomerase II inhibitors were measured in closely related strains of mouse lymphoma L5178Y cells differing in their sensitivity to ionizing radiation. " 01/01/1989 - "Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains." Order ALL the reference details at left...
4.	DNA Damage 01/01/2006 - "The objective of our study was to identify the mode of cell killing and the mechanism behind the increase in topoisomerase II mediated DNA damage. " 05/01/1988 - "The present studies, in addition to emphasizing the role of DNA damage in resistance, also underscore the relative importance of DNA topoisomerase II function in anthracycline cytotoxicity." 05/01/2009 - "One of the primary mechanisms of anthracycline action involves DNA damage caused by inhibition of topoisomerase II. Enzymatic detoxification of anthracycline is a major critical factor that determines anthracycline resistance. " 01/01/2009 - "In this chapter we will outline the comet assay for the detection of DNA damage induced by topoisomerase II inhibitors, cross-linking agents and gamma radiation." 01/01/2009 - "Detection of DNA damage induced by topoisomerase II inhibitors, gamma radiation and crosslinking agents using the comet assay." Order ALL the reference details at left...
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/1995 - "Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines." 11/01/1994 - "Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs." 01/01/1994 - "Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. " 11/18/1992 - "Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line." 04/01/1992 - "Furthermore, in addition to the normal transcript, an abnormally sized topoisomerase II message and a rearrangement of the topoisomerase II gene were detected in a poorly sensitive small cell lung cancer cell line. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Etoposide (VP 16)
2.	Type I DNA Topoisomerases (Topoisomerase I)
3.	DNA (Deoxyribonucleic Acid)
4.	Doxorubicin (Adriamycin)
5.	sobuzoxane
6.	Razoxane (Dexrazoxane)
7.	DNA topoisomerase II alpha
8.	NF-kappa B (NF-kB)
9.	trioctyl phosphine oxide (TOPO)
10.	Amsacrine (AMSA)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Remission Induction
4.	Heterologous Transplantation (Xenotransplantation)
5.	Radiotherapy

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 20715 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>